1 / 27

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN:

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 6: Section 10.3.11. Contents Part 6: Section 10.3.11 4.10. Structure based drug design - Strategy & Procedure (16 slides)

nathanashe
Download Presentation

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 6: Section 10.3.11

  2. Contents Part 6: Section 10.3.11 4.10. Structure based drug design - Strategy & Procedure (16 slides) - Design of Antihypertensives - ACE inhibitors - Carboxypeptidase - Carboxypeptidase mechanism - Inhibition of carboxypeptidase - Lead compounds for ACE inhibitor - Proposed binding mode - Extension and bio-isostere strategies - Extension strategies 4.11. De Novo Drug Design [26 slides]

  3. 4.10 Structure based drug design Strategy Carry out drug design based on the interactions between the lead compound and the target binding site • Procedure • Crystallise target protein with bound ligand (e.g. enzyme + inhibitor or ligand) • Acquire structure by X-ray crystallography • Identify binding site (region where ligand is bound) • Identify binding interactions between ligand and target (modelling) • Identify vacant regions for extra binding interactions (modelling) • ‘Fit’ analogues into binding site to test binding capability (modelling)

  4. 4.10 Structure based drug design Design of Antihypertensives - ACE inhibitors • ACE = Angiotensin converting enzyme • Angiotensin II - hormone which stimulates constriction of blood vessels - causes rise in blood pressure • ACE inhibitors - useful antihypertensive agents • ACE - membrane bound zinc metalloproteinase not easily crystallised • Study analogous enzyme which can be crystallised

  5. 4.10 Structure based drug design Carboxypeptidase

  6. Hydrolysis 4.10 Structure based drug design Carboxypeptidase mechanism

  7. No hydrolysis 4.10 Structure based drug design Inhibition of carboxypeptidase

  8. 4.10 Structure based drug design Lead compounds for ACE inhibitor

  9. 4.10 Structure based drug design Proposed binding mode

  10. 4.10 Structure based drug design Extension and bio-isostere strategies

  11. 4.10 Structure based drug design Extension strategies

  12. 4.11 De Novo Drug Design The design of novel agents based on a knowledge of the target binding site • Procedure • Crystallise target protein with bound ligand • (e.g. enzyme + inhibitor or ligand) • Acquire structure by X-ray crystallography • Identify binding site (region where ligand is bound) • Remove ligand • Identify potential binding regions in the binding site • Design a lead compound to interact with the binding site • Synthesise the lead compound and test it for activity • Crystallise the lead compound with target protein and identify the actual binding interactions • Structure based drug design

More Related